New drug cocktail aims to stall aggressive lung cancer
NCT ID NCT07459634
First seen Mar 11, 2026 · Last updated Jun 19, 2026 · Updated 16 times
Summary
This study tests whether combining two drugs—lurbinectedin and durvalumab—can help keep extensive-stage small-cell lung cancer from progressing after initial treatment. About 50 adults whose cancer did not worsen after standard chemo-immunotherapy will receive the combo as maintenance therapy. The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Valkyrie Clinical Trials, Inc.
Los Angeles, California, 90067, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lurbinectedin (Zepzelca) and durvalumab (Imfinzi)
What this could lead to
If successful, this combination could offer a new maintenance option to delay cancer progression in patients with extensive-stage small-cell lung cancer.
What could go wrong
This is an early Phase 2 trial with only 50 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.